pantoprazole has been researched along with Tuberculosis, Drug-Resistant in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rybniker, J | 1 |
| Vocat, A | 1 |
| Sala, C | 1 |
| Busso, P | 1 |
| Pojer, F | 1 |
| Benjak, A | 1 |
| Cole, ST | 1 |
1 other study available for pantoprazole and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antitubercular Agents; Cell Line; Drug Discovery; | 2015 |